CA2442705A1 - Molecules utilisees a des fins diagnostiques et therapeutiques - Google Patents

Molecules utilisees a des fins diagnostiques et therapeutiques Download PDF

Info

Publication number
CA2442705A1
CA2442705A1 CA002442705A CA2442705A CA2442705A1 CA 2442705 A1 CA2442705 A1 CA 2442705A1 CA 002442705 A CA002442705 A CA 002442705A CA 2442705 A CA2442705 A CA 2442705A CA 2442705 A1 CA2442705 A1 CA 2442705A1
Authority
CA
Canada
Prior art keywords
polynucleotide
cell
proteins
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002442705A
Other languages
English (en)
Inventor
Abel Daffo
Anissa Lee Jones
Alanna-Phung B. Tran
Christopher R. Dahl
Darryl Gietzen
Joyce Chinn
Gerard E. Dufour
Jennifer L. Jackson
Jimmy Y. Yu
Olivia Tuason
Pierre E. Yap
Stefan R. Amshey
Sean C. Daughtery
Tam C. Dam
Tommy F. Liu
Duy-Viet An Nguyen
Yael Kleefeld
Edward H. Gerstin, Jr.
Careyna H. Peralta
Marie H. David
Samantha A. Lewis
Alice J. Chen
Scott R. Panzer
Bernard Harris
Vincent Z. Mullahy-Flores
Rakesh Marwaha
Audrey Lo
Ruth Y. Lan
Michael E. Urashka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Publication of CA2442705A1 publication Critical patent/CA2442705A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des polynucléotides humains purifiés utilisés à des fins diagnostiques et thérapeutiques (dithp). L'invention concerne par ailleurs des polypeptides (DITHP) codés par dithp, l'utilisation de dithp, ou de compléments, d'oligonucléotides, ou de fragments de celle-ci dans des méthodes diagnostiques. De plus, l'invention concerne des vecteurs et des cellules hôtes contenant dithp pour l'expression de DITHP. L'invention concerne en outre l'utilisation de DITHP isolée et purifiée pour induire des anticorps et cribler des banques de composés ainsi que l'utilisation des anticorps anti-DITHP dans des méthodes d'agnostiques. L'invention concerne enfin des micro-réseaux contenant dithp et des méthodes d'utilisation correspondantes.
CA002442705A 2001-03-28 2002-03-27 Molecules utilisees a des fins diagnostiques et therapeutiques Abandoned CA2442705A1 (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US27961901P 2001-03-28 2001-03-28
US60/279,619 2001-03-28
US28006701P 2001-03-29 2001-03-29
US28006801P 2001-03-29 2001-03-29
US60,280,068 2001-03-29
US60/280,067 2001-03-29
US29128001P 2001-05-16 2001-05-16
US60/291,280 2001-05-16
US29184901P 2001-05-17 2001-05-17
US29182901P 2001-05-17 2001-05-17
US60/291,849 2001-05-17
US60,291,829 2001-05-17
US29942801P 2001-06-19 2001-06-19
US60,299,428 2001-06-19
US30000101P 2001-06-20 2001-06-20
US29977601P 2001-06-20 2001-06-20
US60/299,776 2001-06-20
US60/300,001 2001-06-20
PCT/US2002/010056 WO2002097031A2 (fr) 2001-03-28 2002-03-27 Molecules utilisees a des fins diagnostiques et therapeutiques

Publications (1)

Publication Number Publication Date
CA2442705A1 true CA2442705A1 (fr) 2002-12-05

Family

ID=27578771

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002447183A Abandoned CA2447183A1 (fr) 2001-03-28 2002-03-27 Molecules permettant de detecter et de traiter des maladies
CA002442705A Abandoned CA2442705A1 (fr) 2001-03-28 2002-03-27 Molecules utilisees a des fins diagnostiques et therapeutiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002447183A Abandoned CA2447183A1 (fr) 2001-03-28 2002-03-27 Molecules permettant de detecter et de traiter des maladies

Country Status (4)

Country Link
EP (1) EP1383894A2 (fr)
AU (2) AU2002344208A1 (fr)
CA (2) CA2447183A1 (fr)
WO (2) WO2002097031A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110171194A1 (en) * 2004-04-12 2011-07-14 The Trustees Of Columbia University In The City Of New York METHODS AND COMPOSITIONS FOR INHIBITING ABAD/ABeta PROTEIN INTERACTION

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
AU2002250143A1 (en) * 2001-03-16 2002-10-03 Eli Lilly And Company Lp mammalian proteins; related reagents
EP1310552B1 (fr) 2001-11-09 2007-06-13 Proteologics, Inc. Acides nucléiques et polypeptides Posh et procédés associés
US8753822B2 (en) * 2001-12-04 2014-06-17 Wayne State University Neoepitope detection of disease using protein arrays
WO2003099868A2 (fr) * 2002-05-28 2003-12-04 Omrix Biopharmaceuticals Inc. Methode pour obtenir des anticorps anti-idiotype
CA2488382A1 (fr) 2002-06-05 2003-12-18 Case Western Reserve University Methodes et compositions pour detecter des cancers
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
AU2003271149A1 (en) * 2002-10-11 2004-05-04 Yamanouchi Pharmaceutical Co., Ltd. Method of screening remedy for renal failure
WO2004047728A2 (fr) * 2002-11-26 2004-06-10 Genentech, Inc. Compositions et procedes destines au traitement de maladies de nature immune
CA2514461A1 (fr) * 2002-12-27 2004-07-22 National Institute Of Advanced Industrial Science And Technology Glycosyltransferase, acide nucleique codant ladite glycosyltransferase et methode de test de cancerisation a l'aide dudit acide nucleique
GB0315827D0 (en) * 2003-07-05 2003-08-13 Imp College Innovations Ltd Methods
EP1627922A1 (fr) * 2004-08-18 2006-02-22 Sanofi-Aventis Deutschland GmbH Méthode de sélection d'agonistes et d'antagonistes du transporteur de carnitine et son utilisation
GB0423126D0 (en) * 2004-10-18 2004-11-17 Ares Trading Sa Protein
US7727725B2 (en) 2006-04-27 2010-06-01 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
WO2008070090A2 (fr) 2006-12-05 2008-06-12 Oncomed Pharmaceuticals, Inc. Compositions et procédés pour diagnostiquer et traiter un cancer
WO2010053772A2 (fr) 2008-10-29 2010-05-14 The Regents Of The University Of California Antigènes associés à une maladie et leurs procédés d'utilisation
EP2358908B1 (fr) 2008-11-14 2014-01-08 Gen-Probe Incorporated Compositions et procédés pour la détection d'acide nucléique de campylobacter
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
JP6034283B2 (ja) * 2010-03-26 2016-11-30 トラスティーズ・オブ・ダートマス・カレッジ Ｖｉｓｔａ制御性ｔ細胞メディエータタンパク質、ｖｉｓｔａ結合剤、およびその使用
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
KR20130110170A (ko) 2010-09-22 2013-10-08 앨리오스 바이오파마 인크. 치환된 뉴클레오타이드 유사체
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
CN104321333A (zh) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CN105246507B (zh) 2012-09-07 2019-01-25 达特茅斯大学理事会 用于诊断和治疗癌症的vista调节剂
CA3190821A1 (fr) 2013-12-24 2015-07-02 Janssen Pharmaceutica Nv Anticorps et fragments anti-vista
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3154585B1 (fr) 2014-06-11 2022-02-23 Kathy A. Green Utilisation d'antagonistes et d'agonistes vista pour supprimer ou améliorer l'immunité humorale
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
WO2016207717A1 (fr) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anticorps et fragments anti-vista
WO2017137830A1 (fr) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anticorps anti-vista (b7h5)
UA125382C2 (uk) 2016-04-15 2022-03-02 Імьюнекст Інк. Антитіла проти людського vista та їх застосування
US20210223232A1 (en) * 2018-06-26 2021-07-22 Duke University Synthetic odorant receptors
CN110714017B (zh) * 2019-11-06 2023-09-01 河南师范大学 锦鲤ptps基因、编码蛋白及应用
CN111621525B (zh) * 2020-06-18 2021-04-23 中赛干细胞基因工程有限公司 Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途
CN114317732B (zh) * 2021-04-08 2023-08-18 博尔诚（北京）科技有限公司 用于肺癌筛查的组合物及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110171194A1 (en) * 2004-04-12 2011-07-14 The Trustees Of Columbia University In The City Of New York METHODS AND COMPOSITIONS FOR INHIBITING ABAD/ABeta PROTEIN INTERACTION
US8450454B2 (en) * 2004-04-12 2013-05-28 The Trustees Of Columbia University In The City Of New York Compositions for inhibiting ABAD/ABeta protein interaction

Also Published As

Publication number Publication date
AU2002344208A8 (en) 2005-11-17
CA2447183A1 (fr) 2002-10-10
WO2002097031A2 (fr) 2002-12-05
WO2002079449A2 (fr) 2002-10-10
WO2002079449A3 (fr) 2003-03-20
AU2002344208A1 (en) 2002-12-09
WO2002097031A3 (fr) 2005-05-12
EP1383894A2 (fr) 2004-01-28
AU2002338265A1 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
CA2442705A1 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2004023973A2 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
US20040115629A1 (en) Molecules for diagnostics and therapeutics
US20040014087A1 (en) Molecules for diagnostics and therapeutics
JP2004528003A (ja) 細胞外マトリクスおよび細胞接着分子
WO2000073509A2 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
US20040048253A1 (en) Molecules for diagnostics and therapeutics
JP2004516812A (ja) 受容体
JP2003529325A (ja) ヒト輸送タンパク質
JP2004533222A (ja) 免疫グロブリンスーパーファミリータンパク質
JP2004500114A (ja) 転写因子
WO2003062376A2 (fr) Molécules pour le diagnostic et la thérapeutique
WO2001062927A2 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
JP2003532419A (ja) 細胞骨格結合タンパク質
CA2421265A1 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
CA2401868A1 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
CA2449440A1 (fr) Proteines structurelles et associees au cytosquelette
JP2005503751A (ja) 細胞外マトリックスおよび細胞接着分子
CA2385496A1 (fr) Molecules pour le diagnostic et la therapeutique
CA2434677A1 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2003062385A2 (fr) Molecules secretoires
US20040171012A1 (en) Nucleic acid-associated proteins
US20040044184A1 (en) Cytoskeleton-associated proteins
JP2004511208A (ja) Ｒｎａ代謝タンパク質
JP2004509610A (ja) 核内ホルモン受容体

Legal Events

Date Code Title Description
FZDE Discontinued